Contact Kessler Topaz Meltzer & Check, LLP for more information – FOX 5 San Diego
KYTX Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc.
Attention investors, there has been a recent development in the world of securities fraud that you should be aware of. A class action lawsuit has been filed against Kyverna Therapeutics, Inc. If you are a shareholder and have suffered losses, you may be entitled to participate in the lawsuit.
The lawsuit alleges that Kyverna Therapeutics, Inc. made false and misleading statements regarding the results of its Phase 2a clinical trial for KB290, a drug intended to treat NASH. The lawsuit claims that the company misrepresented the effectiveness of the drug, leading to inflated stock prices.
If you are a shareholder who purchased Kyverna Therapeutics, Inc. securities between March 22, 2021, and March 2, 2022, you may be eligible to join the class action lawsuit. It’s important to note that you have until May 20, 2022, to seek appointment as lead plaintiff.
To learn more about your legal rights and options in this case, we encourage you to contact Kessler Topaz Meltzer & Check, LLP. They are available to provide you with information and guidance on how to proceed. Remember, it’s crucial to act quickly if you believe you have suffered losses as a result of securities fraud.
Don’t hesitate to reach out for assistance, as your financial interests may be at stake. Stay informed and stay proactive in protecting your investments.
